Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NvfiledCriticalJanssen Pharmaceutica Nv
Publication of UY30157A1publicationCriticalpatent/UY30157A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente invención consiste en métodos para la neuroproteción, para tratar un trastorno neurodegenerativo agudo, para tratar un trastorno neurodegenerativo crónico y/o para prevenir la muerte o dano neuronal que sigue a un trauma o lesión del cerebro, cabeza y/o médula espinal, que comprende administrar a un sujeto que lo necesite una cantidad terapéuticamente efectiva de uno o más derivados nuevos de benzo-heteroaril sulfamida de fórmula (I) de acuerdo con lo definido en la presente.The present invention consists of methods for neuroprotection, to treat an acute neurodegenerative disorder, to treat a chronic neurodegenerative disorder and / or to prevent death or neuronal damage that follows trauma or injury to the brain, head and / or spinal cord, which comprises administering to a subject in need thereof a therapeutically effective amount of one or more new benzo-heteroaryl sulfamide derivatives of formula (I) as defined herein.
UY30157A2006-02-152007-02-14
USE OF BENZO-HETEROARIL SULFAMIDA DERIVATIVES AS NEUROPROTECTING AGENTS
UY30157A1
(en)
Compounds derived from pyrazolo pyrimidines, inhibitors of pde9; pharmaceutical composition comprising said compounds; Useful in the treatment of a neurodegenerative and cognitive disorder such as Alzheimer's disease and schizophrenia.
Compounds derived from pyridine, urate transporter inhibitors urat 1; pharmaceutical composition that includes them; use for the treatment or prevention of diseases such as gout, hyperuricemia, hypertension, kidney diseases, among others.
Phenyl-3-aza-bicyclo [3.1.0] hex-3-yl-methanone derivative compounds, glycine transporter inhibitors (glyt1); pharmaceutical composition that contains them; pharmaceutical combination; and its use in the treatment of Alzheimer's disease, cognitive disorders in schizophrenia, psychosis, psychiatric disorders, among others